PolTREG announces it has received a Notice of Allowance from the US Patent Office covering the manufacturing of T-regulatory cells (T-reg) to treat Type-1 Diabetes (T1D), and ways the therapy is administered. The decision paves “the way for rapid, unimpeded commercialization of PolTREG’s cell therapies,” CEO Prof. Piotr Trzonkowski was quoted as saying in today’s press … Continued
We are excited to announce that PolTREG will be attending the Biotech Showcase during J.P. Morgan Healthcare Week 2024 in San Francisco, from January 8 to 11. Meet CEO Prof. Piotr Trzonkowski and Chief Business Officer Mariusz Jabłoński to discuss PolTREG’s cutting-edge technology in Treg cell therapies as a promising new form of personalized treatment … Continued
PolTREG has just completed construction of the second phase of one of Europe’s most advanced cell and gene therapy manufacturing facilities, featuring: – 15 stand-alone production lines – annual capacity of 750 batches (of two Treg cell treatments each) – 4000 sq. m of space “The strategic value of our facility is high for several … Continued
Join our CEO Prof. Piotr Trzonkowski at the 16th Polish Transplantation Society Congress inGdansk. On 20 October at 7:45am (room E) Prof. Piotr Trzonkowski will be taking the stage to present acaptivating lecture: Opportunities for Treg cells implementation in transplantation. Mark your calendars, and stay tuned for more details on thispresentation